Biovie is trading 6.47% down now at $2.10, despite broader biotechnology strength and higher major U.S. indexes; no company-specific announcement explaining the September 2, 2026 decline was identified.
- The latest material update, published August 31, reported completion of treatment in the approximately 200-patient ADDRESS-LC Phase 2 trial.
- Topline results are expected before September 30, 2026; the decline appears unexplained and may reflect trading volatility following recent trial-related enthusiasm, rather than a confirmed negative catalyst.